nafamostat has been researched along with Inflammatory Bowel Diseases in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Inflammatory Bowel Diseases: Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim was to determine whether adverse effects of leukocytapheresis (LCAP) are related to nafamostat mesilate (NM) as an anticoagulant." | 1.32 | Detection of specific IgE antibodies to nafamostat mesilate as an indication of possible adverse effects of leukocytapheresis using nafamostat mesilate as anticoagulant. ( Fukunaga, K; Kusaka, T; Matoba, Y; Nagase, K; Ohnishi, K; Sawada, K, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nagase, K | 1 |
| Fukunaga, K | 1 |
| Ohnishi, K | 1 |
| Kusaka, T | 1 |
| Matoba, Y | 1 |
| Sawada, K | 1 |
1 other study available for nafamostat and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
Detection of specific IgE antibodies to nafamostat mesilate as an indication of possible adverse effects of leukocytapheresis using nafamostat mesilate as anticoagulant.
Topics: Adult; Aged; Anticoagulants; Benzamidines; Enzyme-Linked Immunosorbent Assay; Eosinophils; Female; G | 2004 |